WO2022105763A1 - Procédé de traitement d'un cancer gastrique ciblant cd24 - Google Patents

Procédé de traitement d'un cancer gastrique ciblant cd24 Download PDF

Info

Publication number
WO2022105763A1
WO2022105763A1 PCT/CN2021/131010 CN2021131010W WO2022105763A1 WO 2022105763 A1 WO2022105763 A1 WO 2022105763A1 CN 2021131010 W CN2021131010 W CN 2021131010W WO 2022105763 A1 WO2022105763 A1 WO 2022105763A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
antibody
inhibitor
cells
inhibitors
Prior art date
Application number
PCT/CN2021/131010
Other languages
English (en)
Chinese (zh)
Inventor
马斌
高维强
冀露
Original Assignee
上海交通大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海交通大学 filed Critical 上海交通大学
Publication of WO2022105763A1 publication Critical patent/WO2022105763A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Definitions

  • the invention relates to the field of medicine, in particular to a method for treating gastric cancer targeting CD24.
  • Gastric cancer is the fifth most common cancer type in the world and the third most common cause of cancer-related death, with very high morbidity and mortality in East Asian countries such as China.
  • the incidence and mortality of gastric cancer are closely related to regional and environmental factors, such as poor diet, living habits, and Helicobacter pylori infection.
  • Treatment options for early gastric cancer include endoscopic resection, surgery (gastrectomy), antibiotic therapy to eradicate Helicobacter pylori, and adjuvant therapy.
  • endoscopic resection surgery (gastrectomy)
  • antibiotic therapy to eradicate Helicobacter pylori
  • adjuvant therapy treatments for early gastric cancer.
  • some progress has been made in the surgical treatment, postoperative care, and multidisciplinary treatment of gastric cancer, but the prognosis of gastric cancer has improved only slightly. It is very difficult to treat advanced gastric cancer, which is the main reason for the high mortality of gastric cancer.
  • the first-line treatment for advanced gastric cancer is chemotherapy based on platinum drugs and 5-fluorouracil (5-Fu).
  • trastuzumab has been approved for first-line treatment of patients with human epidermal growth factor receptor 2 (HER-2)-positive gastric cancer.
  • HER-2 human epidermal growth factor receptor 2
  • the drug ramucirumab which targets vascular endothelial growth factor (VEGF)
  • VEGF vascular endothelial growth factor
  • the purpose of the present invention is to provide a new gastric cancer targeted therapy method.
  • the first aspect of the present invention provides the use of a CD24 inhibitor for preparing a pharmaceutical composition for preventing and/or treating gastric cancer.
  • the pharmaceutical composition is used to upregulate the infiltration of cells selected from the group consisting of CD4 + T cells, CD8 + T cells, B cells, M1 macrophages, or a combination thereof.
  • the pharmaceutical composition is used to downregulate the infiltration of T (Treg) cells and/or M2 macrophages into tumor tissue.
  • the gastric cancer is gastric cancer that is insensitive to PD-1 and/or PD-L1 inhibitors or gastric cancer that is resistant to PD-1 and/or PD-L1 inhibitors.
  • the gastric cancer is a gastric cancer with high CD24 expression.
  • the gastric cancer is selected from the group consisting of in situ gastric cancer, intestinal-type gastric cancer, diffuse gastric cancer, gastric adenocarcinoma, Helicobacter pylori-induced gastric cancer, or a combination thereof.
  • the gastric cancer is early gastric cancer, intermediate gastric cancer or advanced gastric cancer.
  • the inhibitor is selected from the group consisting of: an antibody or small molecule inhibitor targeting CD24 and/or its receptor protein; a targeting nucleic acid molecule targeting CD24 and/or its receptor gene or a gene editor; or a combination thereof.
  • the small molecule inhibitor includes small molecule inhibitor compounds and pharmaceutically acceptable salts thereof.
  • the CD24 receptor is sialic acid-binding immunoglobulin-like lectin 10 (Siglec-10).
  • the antibody is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, chimeric antibodies, bispecific antibodies, antibody conjugates, small molecule antibodies, antibody fusion proteins, and combinations thereof.
  • the small molecule antibody is selected from the group consisting of single-chain antibody ScFv, Fab antibody, Fv fragment, and combinations thereof.
  • the ScFv antibody includes a secretory single-chain antibody expressed (including overexpressed) in the treatment cells.
  • the therapeutic cells include mesenchymal stem cells, CAR-T cells, TCR-T cells, (CAR-)NK cells, macrophages, and dendritic cells.
  • the inhibitor is selected from the group consisting of: plant extract inhibitor, small molecule compound inhibitor, nucleic acid inhibitor, peptide inhibitor, polysaccharide inhibitor, viral vector inhibitor, lipid inhibitor Plastid carrier inhibitor, or nanoparticle carrier inhibitor.
  • the vector includes: bacterial plasmid, bacteriophage, yeast plasmid, plant cell virus, mammalian cell virus such as adenovirus, retrovirus, or other vectors.
  • the pharmaceutical composition further includes a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of PARP1/2 inhibitors, chemotherapeutic drugs that induce DNA damage in cancer cells, DNA alkyl groups Chemotherapy drugs, DNA or RNA synthesis inhibitors, EGFR, ALK or FGFR tyrosine receptor kinase inhibitors, KRAS, MEK or ERK tumor signaling pathway inhibitors, tumor immunotherapy drugs (such as PD-1 inhibitors, PD -L 1 inhibitor, etc.).
  • the second therapeutic agent is selected from the group consisting of PARP1/2 inhibitors, chemotherapeutic drugs that induce DNA damage in cancer cells, DNA alkyl groups Chemotherapy drugs, DNA or RNA synthesis inhibitors, EGFR, ALK or FGFR tyrosine receptor kinase inhibitors, KRAS, MEK or ERK tumor signaling pathway inhibitors, tumor immunotherapy drugs (such as PD-1 inhibitors, PD -L 1 inhibitor, etc.).
  • the pharmaceutical composition further includes a pharmaceutically acceptable carrier.
  • the dosage form of the pharmaceutical composition is selected from the following group: liquid preparations (such as solution, emulsion, suspension), solid preparations (such as freeze-dried preparations).
  • the dosage form of the pharmaceutical composition is selected from the following group: injection, powder injection, capsule, tablet, pill, powder, granule, syrup, oral liquid or tincture.
  • a second aspect of the present invention provides a method for treating gastric cancer, comprising the steps of: administering a therapeutically effective amount of a CD24 inhibitor to a subject in need, thereby treating gastric cancer.
  • the subject is a mammal.
  • the subject is selected from the group consisting of human, rat or mouse.
  • FIG. 1 The mRNA expression level of CD24 in gastric adenocarcinoma was higher than that in healthy controls in TCGA database analysis;
  • B-C in mouse models induced by Helicobacter Helicobacter felis (H. felis) and carcinogen MNU and in normal controls
  • H. felis Helicobacter Helicobacter felis
  • MNU carcinogen MNU
  • mice the expression of CD24 in gastric epithelial cells was analyzed by flow cytometry, and it was found that the expression of CD24 on the surface of gastric epithelial cell membrane in H.felis/MNU gastric cancer model was higher than that in normal mice. **p ⁇ 0.001, ****p ⁇ 0.0001.
  • FIG. 1 (A) Analysis in the TCGA database found that the mRNA expression level of CD24 in gastric adenocarcinoma was significantly higher than that of the other two immunosuppressive molecules, CD47 and PD-L1; (B) in Helicobacter Helicobacter felis (H. felis) and oncogenic In the mouse model induced by MNU, the expression of three molecules in gastric epithelial cells was analyzed by flow cytometry, and it was found that the expression of CD24 was significantly higher than that of CD47 and PD-L1. **p ⁇ 0.001, ***p ⁇ 0.001.
  • FIG. 4 In a mouse model induced by Helicobacter Helicobacter felis (H. felis) and the carcinogen MNU, tumor-forming mice were intraperitoneally injected with CD24 antibody, PD-1 antibody or IgG control, after 6 weeks of treatment HE staining of gastric tissue sections showed that CD24 antibody could significantly reduce the size of gastric tumors and the abnormal phenotype of glandular structure, while PD-1 antibody had no significant effect.
  • FIG. 5 In a mouse model induced by Helicobacter Helicobacter felis (H. felis) and carcinogen MNU, tumor-forming mice were intraperitoneally injected with CD24 antibody or IgG control, and gastric tissue was flown after 6 weeks of treatment. Cytometry analysis showed that CD24 antibody can significantly increase the proportion of CD4T, CD8T, B cells, and M1 macrophages and other immune cells with anti-tumor functions, and can reduce tumor-promoting regulatory T cells and M2 macrophages. Proportion. *p ⁇ 0.01.
  • the present inventors provide a gastric cancer treatment method by targeting CD24.
  • the present invention finds for the first time that CD24 is significantly highly expressed in gastric cancer cells, and the administration of CD24 antibody can effectively treat gastric cancer. Further, it was found that CD24 antibody can significantly up-regulate the proportion of immune cells with anti-tumor functions such as CD4T, CD8T, B cells and M1-type macrophages, and can up-regulate the proportion of tumor-promoting regulatory T cells and M2-type macrophages. thereby inhibiting gastric cancer.
  • CD24 inhibitors were also found to be able to suppress gastric cancers that are not sensitive to PD-1 and/or PD-L1 inhibitors. The present invention has been completed on this basis.
  • the term “about” means that the value may vary by no more than 1% from the recited value.
  • the expression “about 100” includes all values between 99 and 101 and (eg, 99.1, 99.2, 99.3, 99.4, etc.).
  • the terms "containing” or “including (including)” can be open, semi-closed, and closed. In other words, the term also includes “consisting essentially of,” or “consisting of.”
  • room temperature refers to a temperature of 4-40°C, preferably, 25 ⁇ 5°C.
  • the term "pharmaceutically acceptable” ingredient refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (eg, toxicity, irritation, and allergy), ie, with a reasonable benefit/risk ratio.
  • up-regulate refers to an increase in the amount of an indicator by 1.2-fold, preferably, 1.5-fold, 2.0-fold or 3.0-fold, compared to not administering the active ingredient of the present invention.
  • the term "down-regulated” refers to a reduction in the amount of a certain indicator by a factor of 0.8, preferably, by a factor of 0.5 or 0.3, compared to not administering the active ingredient of the present invention.
  • CD24 also known as a thermostable antigen, is a highly glycosylated glycosylphosphatidylinositol-anchored cell surface protein. CD24 interacts with Siglec-10 molecules on innate immune cells to transmit immunosuppressive signals to suppress inflammatory responses.
  • CD24 inhibitors of the present invention include antibodies or small molecule inhibitors targeting CD24 and/or its receptor proteins; targeting nucleic acid molecules or gene editors targeting CD24 and/or its receptor genes; or combinations thereof.
  • CD24 monoclonal antibodies particularly preferred are CD24 monoclonal antibodies, Siglec-10 monoclonal antibodies, or a combination thereof.
  • the pharmaceutical composition of the present invention contains the above-mentioned CD24 inhibitor as an active ingredient.
  • the pharmaceutical composition of the present invention has a significant effect on the treatment of gastric cancer, and can be used as a drug for the treatment of gastric cancer.
  • the pharmaceutical composition of the present invention can be used for the treatment of gastric cancer in patients who are insensitive to PD-1 and/or PD-L1 inhibitors or resistant to PD-1 and/or PD-L1 inhibitors .
  • the pharmaceutical composition of the present invention comprises the inhibitor of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier within a safe and effective amount.
  • terapéuticaally effective dose refers to any amount of a drug, as described below, that, when used alone or in combination with another therapeutic agent, promotes disease regression, which manifests as disease symptoms decrease the severity of disease, increase the frequency and duration of disease-free periods, or prevent impairment or disability resulting from the disease.
  • a “therapeutically effective dose” of a drug of the present invention also includes a “prophylactically effective dose", which is any amount of the drug as described below, when the amount of the drug is administered alone or in combination with another therapeutic agent In a subject at risk of developing the disease or suffering from relapse of the disease, the occurrence or relapse of the disease can be inhibited.
  • the pharmaceutical composition contains 1-2000 mg of the active ingredient/dose of the present invention, more preferably, 10-500 mg of the active ingredient/dose of the present invention.
  • the "one dose” is a capsule or tablet.
  • “Pharmaceutically acceptable carrier” means: one or more compatible solid or liquid filler or gel substances which are suitable for human use and which must be of sufficient purity and sufficiently low toxicity. "Compatibility” as used herein means that the components of the composition can be blended with the active ingredients of the present invention and with each other without significantly reducing the efficacy of the active ingredients.
  • Examples of pharmaceutically acceptable carrier moieties include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid) , magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween) ), wetting agents (such as sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • cellulose and its derivatives such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • gelatin such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate
  • the mode of administration of the active ingredient or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration medicine.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active ingredient is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) fillers or extenders, such as , starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as hydroxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants , for example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) ) absorption accelerators, such as quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and glyceryl mono
  • Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active ingredient in such compositions may be in a certain part of the digestive tract in a delayed manner. Examples of embedding components that can be employed are polymeric substances and waxes. If desired, the active ingredient may also be in microencapsulated form with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • liquid dosage forms may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-Butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures of these substances, and the like.
  • inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-Butanediol, dimethylformamide
  • compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • Suspensions in addition to the active ingredient, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like .
  • suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like .
  • compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • Dosage forms for topical administration of the active ingredients of the present invention include ointments, powders, patches, sprays and inhalants.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • the active ingredients of the present invention may be administered alone or in combination with other pharmaceutically acceptable therapeutic agents.
  • the pharmaceutical composition further comprises one or more anticancer agents and/or immunosuppressive agents, preferably, the anticancer agents and/or immunosuppressive agents are selected from the group consisting of: PARP1/ 2 Inhibitors, chemotherapy drugs that induce DNA damage in cancer cells, DNA alkylation drugs, DNA or RNA synthesis inhibitors, EGFR, ALK or FGFR tyrosine receptor kinase inhibitors, KRAS, MEK or ERK tumor signaling pathways Inhibitors, tumor immunotherapy drugs (such as PD-1 inhibitors, PD-L 1 inhibitors, etc.).
  • the anticancer agents and/or immunosuppressive agents are selected from the group consisting of: PARP1/ 2 Inhibitors, chemotherapy drugs that induce DNA damage in cancer cells, DNA alkylation drugs, DNA or RNA synthesis inhibitors, EGFR, ALK or FGFR tyrosine receptor kinase inhibitors, KRAS,
  • the pharmaceutical composition further comprises one or more anticancer agents and/or immunosuppressive agents, preferably, the anticancer agents and/or immunosuppressive agents are selected from the group consisting of: Panib, Lukapanib, Niraparib, Methotrexate, Capecitabine, Gemcitabine, Deoxyfluridine, Pemetrexed Disodium, Pazopanib, Imatinib, Errol tinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab, trastuzumab, paclitaxel, vinorelbine, docetaxel, Doxorubicin, Hydroxycamptothecin, Mitomycin, Epirubicin, Pirarubicin, Bleomycin, Letrozole, Tamoxifen, Fulvestrant, Triptorelin, Fluta Amine, leuprolide, anastrozole, ifosfamide, busulfan,
  • an active ingredient of the present invention is administered to a cancer-affected subject in combination with other conventional cancer treatments, eg, radiation therapy or surgery.
  • Radiation therapy is well known in the art and includes X-ray therapy, such as gamma radiation, and radiopharmaceutical therapy.
  • the active ingredients of the present invention are administered concomitantly with, or sequentially with, other agents as part of a combination therapy regimen, in the same or separate formulations.
  • Typical ranges for therapeutically effective doses of compositions of active ingredients of the present invention will be: about 1-2000 mg/day, about 10 to about 1000 mg/day, about 10 to about 500 mg/day, about 10 to about 250 mg/day, about 10 to about 100 mg/day, or about 10 to about 50 mg/day.
  • a therapeutically effective dose will be administered in one or more doses. It is to be understood, however, that the particular dosage of a compound of the present invention for any particular patient will depend on a variety of factors, eg, the age, sex, weight, general health, diet, individual response, time of administration, and treatment of the patient to be treated. disease severity, activity of the particular compound administered, dosage form, mode of application, and concomitant medications.
  • a therapeutically effective amount for a given situation can be determined using routine experimentation and is within the ability and judgment of the clinician or physician.
  • the compound or composition will be administered in multiple doses based on the individual condition of the patient and in a manner that allows delivery of a therapeutically effective amount.
  • the present invention finds for the first time that a CD24 inhibitor can effectively treat gastric cancer, and provides a therapeutic method for treating gastric cancer by targeting CD24.
  • the method of the present invention can be used to treat intermediate and advanced gastric cancer.
  • CD24 inhibitors can treat gastric cancer that is not sensitive to PD-1 inhibitors, thereby providing a new treatment method for such patients.
  • CD3e 145-2C11
  • CD11c N4108
  • CD11b M1/70
  • CD279 PD-1; 29F.1A12
  • F4/80 BM8
  • CD24 CD24(M1/69)
  • MHC-II MHC-II(I-A/ I-E; M5/114.15.2) from BioLegend
  • CD4 (GK1.5) and CD8a 53-6.7) from BD Biosciences
  • CD45 (30-F11) and Ly-6G/Ly-6C (Gr1; RB6-8C5) ) were purchased from eBioscience.
  • H. felis Helicobacter pylori
  • MNU N-methyl-N-nitrosourea
  • CD24 may be a more ideal therapeutic target than CD47 and PD-L1 in gastric cancer.
  • Treatment regimen for gastric cancer mice For antibody treatment, starting from 37 weeks after starting to treat mice with MNU drinking water, 50 ⁇ g CD24 monoclonal antibody/mouse/needle (R&D Systems), 100 ⁇ g PD-1 monoclonal antibody was injected twice a week Clone antibody/only/needle (Bio X Cell) or control IgG. Continuous treatment for 6 weeks. Mice were sacrificed after treatment, and gastric tissue was examined.
  • CD24 antibody As shown in Figure 3, in the gastric cancer mouse model, CD24 antibody, PD-1 antibody or IgG control were intraperitoneally injected into the tumor-forming mice.
  • the PD-1 antibody had no significant effect. This suggests that CD24 antibody can be used for the treatment of advanced gastric cancer, especially gastric cancer that is insensitive and/or resistant to PD-1.
  • CD24 antibody can significantly increase the proportion of immune cells with anti-tumor functions such as CD4T, CD8T, B cells and M1 macrophages, and can reduce the tumor-promoting regulatory T The proportion of cells and M2 macrophages.
  • CD24 antibody was found to have a very good therapeutic effect.
  • the mechanism by which CD24 exerts its effect is to increase the infiltration of effector T cells (especially CD4 + and CD8 + T cells) and reduce the infiltration of regulatory T cells.
  • treatment also It promoted the transformation of tumor-associated macrophages from M2 type to M1 type, suggesting that by CD24 antibody treatment, the immune effect was aroused in mice to fight against the immunosuppressed tumor microenvironment, inhibit tumor progression, and achieve good therapeutic effects.
  • thermostable antigen CD24 is an important tumor stem cell marker in tissues and tumor stem cells, and is closely related to tumor metastasis and invasion. In addition, it is widely used as a marker for differentiating hematopoietic cells and neuronal cells. High levels of CD24 expression are found in many different tumor types, and in a new study, researchers have also identified CD24 as a new 'don't eat me' signal ), suggesting that CD24 is a potential target for cancer immunotherapy.
  • CD24 is usually widely expressed in tumor cells, it does not mean that inhibiting CD24 can definitely have a therapeutic effect on cancer. Cancers such as leukemia are not sensitive to CD24 inhibitors, so the method of inhibiting CD24 for cancer treatment still needs further research.
  • the present invention proves the remarkable curative effect of CD24 inhibitor on gastric cancer (especially middle-advanced gastric cancer) through experiments for the first time, thereby providing a new gastric cancer treatment method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de traitement d'un cancer gastrique ciblant CD24. L'invention concerne spécifiquement l'utilisation d'un inhibiteur de CD24 pour préparer une composition pharmaceutique, la composition pharmaceutique étant utilisée pour la prévention et/ou le traitement d'un cancer gastrique. Selon la présente invention, il a été découvert que les inhibiteurs de CD24 pouvaient être utilisés pour le traitement du cancer gastrique, permettant ainsi d'obtenir un nouveau procédé de traitement ciblé pour le cancer gastrique.
PCT/CN2021/131010 2020-11-19 2021-11-16 Procédé de traitement d'un cancer gastrique ciblant cd24 WO2022105763A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011302899.4A CN114533872B (zh) 2020-11-19 2020-11-19 靶向cd24的胃癌治疗方法
CN202011302899.4 2020-11-19

Publications (1)

Publication Number Publication Date
WO2022105763A1 true WO2022105763A1 (fr) 2022-05-27

Family

ID=81659263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/131010 WO2022105763A1 (fr) 2020-11-19 2021-11-16 Procédé de traitement d'un cancer gastrique ciblant cd24

Country Status (2)

Country Link
CN (1) CN114533872B (fr)
WO (1) WO2022105763A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065769A1 (en) * 2011-09-08 2013-03-14 The Regents Of The University Of California Salivary biomarkers for gastric cancer detection
US20180344829A1 (en) * 2015-11-17 2018-12-06 Innate Pharma Siglec-10 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103194429A (zh) * 2012-01-05 2013-07-10 中美冠科生物技术(北京)有限公司 人胃癌肿瘤干细胞株gam-016s的培养建立
CN106338605B (zh) * 2016-08-24 2019-06-21 厦门大学附属中山医院 周围神经髓鞘蛋白22作为胃癌干细胞及耐药细胞标志物的用途
CN111073979B (zh) * 2019-12-31 2021-08-17 上海交通大学 阻断ccl28趋化通路的胃癌治疗方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065769A1 (en) * 2011-09-08 2013-03-14 The Regents Of The University Of California Salivary biomarkers for gastric cancer detection
US20180344829A1 (en) * 2015-11-17 2018-12-06 Innate Pharma Siglec-10 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG YING-CHAO, JI-LIN WANG • XUAN KONG • TIAN-TIAN SUN • HAO-YAN CHEN • JIE HONG • JING-YUAN FANG: "CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation", APOPTOSIS, vol. 19, 11 December 2013 (2013-12-11), XP055931639, DOI: 10.1007/s10495-013-0949-9 *

Also Published As

Publication number Publication date
CN114533872A (zh) 2022-05-27
CN114533872B (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
Ferrere et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
US8632772B2 (en) Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
CN110996952A (zh) 用于治疗癌症的方法
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
CN110381938A (zh) 减少中性粒细胞缺乏症的方法
US20200405748A1 (en) Method of treating severe forms of pulmonary hypertension
CN107921108A (zh) 用于治疗癌症的hdac抑制剂和抗‑pd‑l1抗体的组合
WO2014142220A1 (fr) Agent antitumoral
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
WO2021182573A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
KR20210120022A (ko) 종양 치료용 복합 약제학적 조성물
WO2020249018A1 (fr) Composition pharmaceutique combinée pour le traitement du cancer du poumon positif aux gènes "conducteurs"
Tong et al. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy
WO2022105763A1 (fr) Procédé de traitement d'un cancer gastrique ciblant cd24
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
WO2019129168A1 (fr) Utilisation d'un traitement associant un anticorps anti-pd-1 et l'apatinib pour traiter le cancer du sein triple négatif
WO2023210042A1 (fr) Médicament pour le traitement et/ou la prévention d'une tumeur exprimant l'il-34
CN113769096B (zh) 6-磷酸葡萄糖脱氢酶抑制剂的医药用途
US20210154265A1 (en) Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment
WO2021031998A1 (fr) Polypeptides recombinés et leurs utilisations
Bailey Genetic and Pharmaceutical Targeting of HIF-1α Enhances PD-L1 Expression in Normal Tissue while Repressing It in Cancer: An Optimal Strategy for Combination Immunotherapy
US20230255904A1 (en) Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
WO2024015757A1 (fr) Combinaison d'abémaciclib et de vénétoclax destinée à être utilisée dans le traitement du lymphome à cellules du manteau (mcl)
CN117379551A (zh) 一种肿瘤联合治疗疗法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21893910

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21893910

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21893910

Country of ref document: EP

Kind code of ref document: A1